PCVX Q1 2022 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$39M

EPS (Diluted)

$-0.68

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$31M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$403M

Total Liabilities

$43M

Stockholders' Equity

$360M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$23M	-69.5%
Net Income	-$39M	-$21M	-83.7%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%